These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20520537)

  • 1. ALLHAT: still providing correct answers after 7 years.
    Einhorn PT; Davis BR; Wright JT; Rahman M; Whelton PK; Pressel SL;
    Curr Opin Cardiol; 2010 Jul; 25(4):355-65. PubMed ID: 20520537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.
    Wright JT; Probstfield JL; Cushman WC; Pressel SL; Cutler JA; Davis BR; Einhorn PT; Rahman M; Whelton PK; Ford CE; Haywood LJ; Margolis KL; Oparil S; Black HR; Alderman MH;
    Arch Intern Med; 2009 May; 169(9):832-42. PubMed ID: 19433694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
    Einhorn PT; Davis BR; Massie BM; Cushman WC; Piller LB; Simpson LM; Levy D; Nwachuku CE; Black HR;
    Am Heart J; 2007 Jan; 153(1):42-53. PubMed ID: 17174636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive prescribing practices: impact of the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
    Player MS; Gill JM; Fagan HB; Mainous AG
    J Clin Hypertens (Greenwich); 2006 Dec; 8(12):860-4. PubMed ID: 17170611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
    Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
    Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization.
    Xie F; Petitti DB; Chen W
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):464-9. PubMed ID: 15831354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
    Oparil S; Davis BR; Cushman WC; Ford CE; Furberg CD; Habib GB; Haywood LJ; Margolis K; Probstfield JL; Whelton PK; Wright JT;
    Hypertension; 2013 May; 61(5):977-86. PubMed ID: 23529173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Chen YJ; Li LJ; Tang WL; Song JY; Qiu R; Li Q; Xue H; Wright JM
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008170. PubMed ID: 30480768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].
    Kuwajima I
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():648-53. PubMed ID: 15171450
    [No Abstract]   [Full Text] [Related]  

  • 12. What are the best first-line antihypertensives: answers and more questions from the ALLHAT study.
    Salam AM
    Expert Opin Investig Drugs; 2003 May; 12(5):879-85. PubMed ID: 12720498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
    Wright JT; Dunn JK; Cutler JA; Davis BR; Cushman WC; Ford CE; Haywood LJ; Leenen FH; Margolis KL; Papademetriou V; Probstfield JL; Whelton PK; Habib GB;
    JAMA; 2005 Apr; 293(13):1595-608. PubMed ID: 15811979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALLHAT, or the soft science of the secondary end point.
    Messerli FH
    Ann Intern Med; 2003 Nov; 139(9):777-80. PubMed ID: 14597462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiazide and loop diuretics.
    Sica DA; Carter B; Cushman W; Hamm L
    J Clin Hypertens (Greenwich); 2011 Sep; 13(9):639-43. PubMed ID: 21896142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
    Rahman M; Ford CE; Cutler JA; Davis BR; Piller LB; Whelton PK; Wright JT; Barzilay JI; Brown CD; Colon PJ; Fine LJ; Grimm RH; Gupta AK; Baimbridge C; Haywood LJ; Henriquez MA; Ilamaythi E; Oparil S; Preston R;
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):989-1002. PubMed ID: 22490878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of ALLHAT publication on antihypertensive prescribing patterns in Regione Emilia-Romagna, Italy.
    Maio V; Gagne JJ
    J Clin Pharm Ther; 2010 Feb; 35(1):55-61. PubMed ID: 20175812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
    Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
    Pharmacogenet Genomics; 2009 Jun; 19(6):415-21. PubMed ID: 19352213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are thiazide diuretics preferred as first-line therapy for hypertension? An appraisal of The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Scott I; Stowasser M
    Intern Med J; 2003 Jul; 33(7):327-30. PubMed ID: 12823686
    [No Abstract]   [Full Text] [Related]  

  • 20. [The ALLHAT study (antihypertensive and lipid-lowering treatment to prevent heart attack trial): primary antihypertensive agents - diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors].
    Scholze J; Unger T
    Internist (Berl); 2003 Sep; 44(9):1193-5. PubMed ID: 14566471
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.